Sign in

    Maizi Ali Mohamed

    Senior Equity Research Analyst at Leerink Partners LLC

    Maizi Alimohamed, M.D., MPH is a Senior Equity Research Analyst at Leerink Partners LLC specializing in cardiovascular, endocrine disorders, and infectious disease sectors. He covers companies including Amarin Corporation plc, Xencor, Inc., and Zai Lab Ltd, consistently delivering rigorous investment research reflected in accurate earnings and price projections for covered firms. Alimohamed began his biopharmaceutical equity research career prior to joining Leerink Partners, and has built a track record of performance through progressive analyst roles in prominent healthcare investment firms. He is professionally credentialed as an M.D. and MPH, and is registered with FINRA, holding relevant securities licenses.

    Maizi Ali Mohamed's questions to AMARIN CORP PLC\UK (AMRN) leadership

    Maizi Ali Mohamed's questions to AMARIN CORP PLC\UK (AMRN) leadership • Q3 2024

    Question

    Maizi Ali Mohamed of Leerink Partners inquired about the outlook for VASCEPA's net pricing in the U.S. amid increasing rebates and asked if additional clinical trials could accelerate reimbursement for VAZKEPA in the EU and China.

    Answer

    President and CEO Aaron Berg acknowledged that U.S. rebate pressures will likely continue due to generic competition but stated the company can still compete profitably. Regarding European reimbursement, Dr. Steven Ketchum, EVP of R&D, and Mr. Berg explained that while they continue to generate supportive data, they believe their current clinical package is strong and that reimbursement timelines are more reflective of broad market challenges in Europe rather than a data deficiency. They noted a focus on high-risk patient subgroups is helping accelerate uptake.

    Ask Fintool Equity Research AI